Anti-DFS70/LEDGF Antibodies Are More Prevalent in Healthy Individuals Compared to Patients with Systemic Autoimmune Rheumatic Diseases

REFERENCES

1. 1.↵
   1. Mahler M,
   2. Fritzler MJ

   . Epitope specificity and significance in systemic autoimmune diseases. Ann NY Acad Sci 2010;1183:267–87.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Meroni PL,
   2. Schur PH

   . ANA screening: An old test with new recommendations. Ann Rheum Dis 2010;69:1420–2.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Ochs RL,
   2. Stein TW Jr.,
   3. Peebles CL,
   4. Gittes RF,
   5. Tan EM

   . Autoantibodies in interstitial cystitis. J Urol 1994;151:587–92.

   OpenUrlPubMed
4. 4.↵
   1. Ganapathy V,
   2. Casiano CA

   . Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): What exactly are the autoantibodies trying to tell us? Arthritis Rheum 2004;50:684–8.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Ochs RL,
   2. Muro Y,
   3. Si Y,
   4. Ge H,
   5. Chan EK,
   6. Tan EM

   . Autoantibodies to DFS 70 kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol 2000;105:1211–20.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Shinohara T,
   2. Singh DP,
   3. Chylack LT Jr.

   . Review: Age-related cataract: immunity and lens epithelium-derived growth factor (LEDGF). J Ocul Pharmacol Ther 2000;16:181–91.

   OpenUrlPubMed
7. 7.↵
   1. Daniels T,
   2. Zhang J,
   3. Gutierrez I,
   4. Elliot ML,
   5. Yamada B,
   6. Heeb MJ,
   7. et al.

   Antinuclear autoantibodies in prostate cancer: Immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate 2005;62:14–26.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Maertens G,
   2. Cherepanov P,
   3. Pluymers W,
   4. Busschots K,
   5. De Clercq E,
   6. Debyser Z,
   7. et al.

   LEDGF/p75 is essential for nuclear and chromosomal targeting of HIV-1 integrase in human cells. J Biol Chem 2003;278:33528–39.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Watanabe A,
   2. Kodera M,
   3. Sugiura K,
   4. Usuda T,
   5. Tan EM,
   6. Yakasaki Y,
   7. et al.

   Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum 2004;50:892–900.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Dellavance A,
    2. Viana VS,
    3. Leon EP,
    4. Bonfa ES,
    5. Andrade LE,
    6. Leser PG

    . The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J Rheumatol 2005;32:2144–9.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Yamada K,
    2. Senju S,
    3. Shinohara T,
    4. Nakatsura T,
    5. Murata Y,
    6. Ishihara M,
    7. et al.

    Humoral immune response directed against LEDGF in patients with VKH. Immunol Lett 2001;78:161–8.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Ayaki M,
    2. Ohoguro N,
    3. Azuma N,
    4. Majima Y,
    5. Yata K,
    6. Ibaraki N,
    7. et al.

    Detection of cytotoxic anti-LEDGF autoantibodies in atopic dermatitis. Autoimmunity 2002;35:319–27.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Mariz HA,
    2. Sato EI,
    3. Barbosa SH,
    4. Rodrigues SH,
    5. Dellavance A,
    6. Andrade LE

    . Pattern on the antinuclear antibody-HEp-2 is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum 2011;63:191–200.

    OpenUrlCrossRefPubMed
14. 14.↵
    1. Muro Y,
    2. Sugiura K,
    3. Morita Y,
    4. Tomita Y

    . High concomitance of disease marker autoantibodies in anti-DFS70/LEDGF autoantibody-positive patients with autoimmune rheumatic disease. Lupus 2008;17:171–6.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Mahler M,
    2. Hanly JG,
    3. Fritzler MJ

    . Importance of the dense fine speckled pattern on HEp-2 cells and anti-DFS70 antibodies for the diagnosis of systemic autoimmune diseases. Autoimmun Rev 2012;11:642–5.

    OpenUrlCrossRefPubMed
16. 16.↵
    1. Muro Y,
    2. Ogawa Y,
    3. Sugiura K,
    4. Tomita Y

    . HLA-associated production of anti-DFS70/LEDGF autoantibodies and systemic autoimmune disease. J Autoimmun 2006;26:252–7.

    OpenUrlCrossRefPubMed
17. 17.↵
    1. Tan EM,
    2. Cohen AS,
    3. Fries JF,
    4. Masi AT,
    5. McShane DJ,
    6. Rothfield NF,
    7. et al.

    The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271–7.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Narain S,
    2. Richards HB,
    3. Satoh M,
    4. Sarmiento M,
    5. Davidson R,
    6. Shuster J,
    7. et al.

    Diagnostic accuracy for lupus and other systemic autoimmune diseases in the community setting. Arch Intern Med 2004;164:2435–41.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Arbuckle MR,
    2. McClain MT,
    3. Rubertone MV,
    4. Scofield RH,
    5. Dennis GJ,
    6. James JA,
    7. et al.

    Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003;349:1526–33.

    OpenUrlCrossRefPubMed
20. 20.↵
    1. Eriksson C,
    2. Kokkonen H,
    3. Johansson M,
    4. Hallmans G,
    5. Wadell G,
    6. Rantapaa-Dahlqvist S

    . Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther 2011;13:R30.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. Fritzler MJ

    . The antinuclear antibody test: Last or lasting gasp? Arthritis Rheum 2011;63:19–22.

    OpenUrlCrossRefPubMed
22. 22.↵
    1. Mahler M,
    2. Fritzler MJ,
    3. Bluthner M

    . Identification of a SmD3 epitope with a single symmetrical dimethylation of an arginine residue as a specific target of a subpopulation of anti-Sm antibodies. Arthritis Res Ther 2005;7:R19–R29.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Chan EK,
    2. Fritzler MJ,
    3. Wiik A,
    4. Andrade LE,
    5. Reeves WH,
    6. Tincani A,
    7. et al.

    AutoAbSC.Org — Autoantibody Standardization Committee in 2006. Autoimmun Rev 2007;6:577–80.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Mahler M,
    2. Radice A,
    3. Sinico RA,
    4. Damoiseaux J,
    5. Seaman A,
    6. Buckmelter K,
    7. et al.

    Performance evaluation of a novel chemiluminescence assay for detection of anti-GBM antibodies: An international multicenter study. Nephrol Dial Transplant 2012;27:243–52.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Ogawa Y,
    2. Sugiura K,
    3. Watanabe A,
    4. Kunimatsu M,
    5. Mishima M,
    6. Tomita Y,
    7. et al.

    Autoantigenicity of DFS70 is restricted to the conformational epitope of C-terminal alpha-helical domain. J Autoimmun 2004;23:221–31.

    OpenUrlCrossRefPubMed
26. 26.
    1. Watanabe K,
    2. Muro Y,
    3. Sugiura K,
    4. Tomita Y

    . IgE and IgG(4) autoantibodies against DFS70/LEDGF in atopic dermatitis. Autoimmunity 2011;44:511–9.

    OpenUrlCrossRefPubMed
27. 27.↵
    1. Bizzaro N,
    2. Tonutti E,
    3. Visentini D,
    4. Alessio MG,
    5. Platzgummer S,
    6. Morozzi G,
    7. et al.

    Antibodies to the lens and cornea in anti-DFS70-positive subjects. Ann NY Acad Sci 2007;1107:174–83.

    OpenUrlCrossRefPubMed
28. 28.↵
    1. Shoenfeld Y,
    2. Toubi E

    . Protective autoantibodies: Role in homeostasis, clinical importance, and therapeutic potential. Arthritis Rheum 2005;52:2599–606.

    OpenUrlCrossRefPubMed
29. 29.↵
    1. Satoh M,
    2. Chan EK,
    3. Ho LA,
    4. Rose KM,
    5. Parks CG,
    6. Cohn RD,
    7. et al.

    Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012;64:2319–27.

    OpenUrlCrossRefPubMed
30. 30.↵
    1. Li QZ,
    2. Karp DR,
    3. Quan J,
    4. Branch VK,
    5. Zhou J,
    6. Lian Y,
    7. et al.

    Risk factors for ANA positivity in healthy persons. Arthritis Res Ther 2011;13:R38.

    OpenUrlCrossRefPubMed
31. 31.↵
    1. Mahler M,
    2. Ngo JT,
    3. Schulte-Pelkum J,
    4. Luettich T,
    5. Fritzler MJ

    . Limited reliability of the indirect immunofluorescence technique for the detection of anti-Rib-P antibodies. Arthritis Res Ther 2008;10:R131.

    OpenUrlCrossRefPubMed
32. 32.↵
    1. Mahler M,
    2. Silverman ED,
    3. Fritzler MJ

    . Novel diagnostic and clinical aspects of anti-PCNA antibodies detected by novel detection methods. Lupus 2010;19:1527–33.

    OpenUrlAbstract/FREE Full Text
33. 33.↵
    1. Bizzaro N,
    2. Tonutti E,
    3. Villalta D

    . Recognizing the dense fine speckled/lens epithelium-derived growth factor/p75 pattern on HEP-2 cells: Not an easy task! Comment on the article by Mariz et al. Arthritis Rheum 2011;63:4036–7.

    OpenUrlCrossRefPubMed